These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 20233783)

  • 1. A potential inhibitory role for the new truncated variant of somatostatin receptor 5, sst5TMD4, in pituitary adenomas poorly responsive to somatostatin analogs.
    Durán-Prado M; Saveanu A; Luque RM; Gahete MD; Gracia-Navarro F; Jaquet P; Dufour H; Malagón MM; Culler MD; Barlier A; Castaño JP
    J Clin Endocrinol Metab; 2010 May; 95(5):2497-502. PubMed ID: 20233783
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Somatostatin and dopamine-somatostatin multiple ligands directed towards somatostatin and dopamine receptors in pituitary adenomas.
    Saveanu A; Gunz G; Guillen S; Dufour H; Culler MD; Jaquet P
    Neuroendocrinology; 2006; 83(3-4):258-63. PubMed ID: 17047391
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Truncated somatostatin receptor variant sst5TMD4 confers aggressive features (proliferation, invasion and reduced octreotide response) to somatotropinomas.
    Luque RM; Ibáñez-Costa A; Neto LV; Taboada GF; Hormaechea-Agulla D; Kasuki L; Venegas-Moreno E; Moreno-Carazo A; Gálvez MÁ; Soto-Moreno A; Kineman RD; Culler MD; Gahete MD; Gadelha MR; Castaño JP
    Cancer Lett; 2015 Apr; 359(2):299-306. PubMed ID: 25637790
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic abnormalities of somatostatin receptors in pituitary tumors.
    Lania A; Mantovani G; Spada A
    Mol Cell Endocrinol; 2008 May; 286(1-2):180-6. PubMed ID: 17913341
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Truncated somatostatin receptor 5 may modulate therapy response to somatostatin analogues--Observations in two patients with acromegaly and severe headache.
    Marina D; Burman P; Klose M; Casar-Borota O; Luque RM; Castaño JP; Feldt-Rasmussen U
    Growth Horm IGF Res; 2015 Oct; 25(5):262-7. PubMed ID: 26188991
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification and characterization of two novel truncated but functional isoforms of the somatostatin receptor subtype 5 differentially present in pituitary tumors.
    Durán-Prado M; Gahete MD; Martínez-Fuentes AJ; Luque RM; Quintero A; Webb SM; Benito-López P; Leal A; Schulz S; Gracia-Navarro F; Malagón MM; Castaño JP
    J Clin Endocrinol Metab; 2009 Jul; 94(7):2634-43. PubMed ID: 19401364
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Somatostatin (SRIF) receptor subtype 2 and 5 gene expression in growth hormone-secreting pituitary adenomas: the relationship with endogenous srif activity and response to octreotide.
    Park C; Yang I; Woo J; Kim S; Kim J; Kim Y; Sohn S; Kim E; Lee M; Park H; Jung J; Park S
    Endocr J; 2004 Apr; 51(2):227-36. PubMed ID: 15118275
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Octreotide and pasireotide (dis)similarly inhibit pituitary tumor cells in vitro.
    Ibáñez-Costa A; Rivero-Cortés E; Vázquez-Borrego MC; Gahete MD; Jiménez-Reina L; Venegas-Moreno E; de la Riva A; Arráez MÁ; González-Molero I; Schmid HA; Maraver-Selfa S; Gavilán-Villarejo I; García-Arnés JA; Japón MA; Soto-Moreno A; Gálvez MA; Luque RM; Castaño JP
    J Endocrinol; 2016 Nov; 231(2):135-145. PubMed ID: 27587848
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dopamine receptor subtype 2 and somatostatin receptor subtype 5 expression influences somatostatin analogs effects on human somatotroph pituitary adenomas in vitro.
    Zatelli MC; Piccin D; Tagliati F; Bottoni A; Ambrosio MR; Margutti A; Scanarini M; Bondanelli M; Culler MD; degli Uberti EC
    J Mol Endocrinol; 2005 Oct; 35(2):333-41. PubMed ID: 16216913
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The new truncated somatostatin receptor variant sst5TMD4 is associated to poor prognosis in breast cancer and increases malignancy in MCF-7 cells.
    Durán-Prado M; Gahete MD; Hergueta-Redondo M; Martínez-Fuentes AJ; Córdoba-Chacón J; Palacios J; Gracia-Navarro F; Moreno-Bueno G; Malagón MM; Luque RM; Castaño JP
    Oncogene; 2012 Apr; 31(16):2049-61. PubMed ID: 21927030
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression and function of somatostatin receptor subtype 1 in human growth hormone secreting pituitary tumors deriving from patients partially responsive or resistant to long-term treatment with somatostatin analogs.
    Matrone C; Pivonello R; Colao A; Cappabianca P; Cavallo LM; Del Basso De Caro ML; Taylor JE; Culler MD; Lombardi G; Di Renzo GF; Annunziato L
    Neuroendocrinology; 2004 Mar; 79(3):142-8. PubMed ID: 15103227
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [New medical treatments in pituitary adenomas].
    Drutel A; Caron P; Archambeaud F
    Ann Endocrinol (Paris); 2008 Sep; 69 Suppl 1():S16-28. PubMed ID: 18954854
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of somatostatin-14 and the receptor-specific somatostatin analogs on chromogranin A and alpha-subunit (alpha-SU) release from "clinically nonfunctioning" pituitary adenoma cells incubated in vitro.
    Pawlikowski M; Lawnicka H; Pisarek H; Kunert-Radek J; Radek M; Culler MD
    J Physiol Pharmacol; 2007 Mar; 58(1):179-88. PubMed ID: 17440235
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BIM-23A760 influences key functional endpoints in pituitary adenomas and normal pituitaries: molecular mechanisms underlying the differential response in adenomas.
    Ibáñez-Costa A; López-Sánchez LM; Gahete MD; Rivero-Cortés E; Vázquez-Borrego MC; Gálvez MA; de la Riva A; Venegas-Moreno E; Jiménez-Reina L; Moreno-Carazo A; Tinahones FJ; Maraver-Selfa S; Japón MA; García-Arnés JA; Soto-Moreno A; Webb SM; Kineman RD; Culler MD; Castaño JP; Luque RM
    Sci Rep; 2017 Feb; 7():42002. PubMed ID: 28181484
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bim-23244, a somatostatin receptor subtype 2- and 5-selective analog with enhanced efficacy in suppressing growth hormone (GH) from octreotide-resistant human GH-secreting adenomas.
    Saveanu A; Gunz G; Dufour H; Caron P; Fina F; Ouafik L; Culler MD; Moreau JP; Enjalbert A; Jaquet P
    J Clin Endocrinol Metab; 2001 Jan; 86(1):140-5. PubMed ID: 11231991
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relevance of coexpression of somatostatin and dopamine D2 receptors in pituitary adenomas.
    Saveanu A; Jaquet P; Brue T; Barlier A
    Mol Cell Endocrinol; 2008 May; 286(1-2):206-13. PubMed ID: 18241980
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of 17beta-estradiol on somatostatin receptor expression and inhibitory effects on growth hormone and prolactin release in rat pituitary cell cultures.
    Djordjijevic D; Zhang J; Priam M; Viollet C; Gourdji D; Kordon C; Epelbaum J
    Endocrinology; 1998 May; 139(5):2272-7. PubMed ID: 9564833
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In Vitro Head-to-Head Comparison Between Octreotide and Pasireotide in GH-Secreting Pituitary Adenomas.
    Gatto F; Feelders RA; Franck SE; van Koetsveld PM; Dogan F; Kros JM; Neggers SJCMM; van der Lely AJ; Lamberts SWJ; Ferone D; Hofland LJ
    J Clin Endocrinol Metab; 2017 Jun; 102(6):2009-2018. PubMed ID: 28323931
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DG3173 (somatoprim), a unique somatostatin receptor subtypes 2-, 4- and 5-selective analogue, effectively reduces GH secretion in human GH-secreting pituitary adenomas even in Octreotide non-responsive tumours.
    Plöckinger U; Hoffmann U; Geese M; Lupp A; Buchfelder M; Flitsch J; Vajkoczy P; Jakob W; Saeger W; Schulz S; Dohrmann C
    Eur J Endocrinol; 2012 Feb; 166(2):223-34. PubMed ID: 22065857
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Somatostatin receptor expression and patients' response to targeted medical treatment in pituitary tumors: evidences and controversies.
    Gatto F; Arvigo M; Ferone D
    J Endocrinol Invest; 2020 Nov; 43(11):1543-1553. PubMed ID: 32557353
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.